1 Pulmonary and Critical Care Medicine Section, Medical Service, Department of Veterans Affairs Medical Center, San Francisco 94121; 2 Cardiovascular Research Institute and Department of Medicine, University of California, San Francisco, CA 94143-0911; and 3 Division of Therapeutics, University Hospital, Nottingham NG7 2UH, United Kingdom
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We reported
previously that mast cell tryptase is a growth factor for dog tracheal
smooth muscle cells. The goals of our current experiments were to
determine if tryptase also is mitogenic in cultured human airway smooth
muscle cells, to compare its strength as a growth factor with that of
other mitogenic serine proteases, and to determine whether its
proteolytic actions are required for mitogenesis. Highly purified
preparations of human lung -tryptase (1-30 nM) caused
dose-dependent increases in DNA synthesis in human airway smooth muscle
cells. Maximum tryptase-induced increases in DNA synthesis far exceeded
those occurring in response to coagulation cascade proteases, such as
thrombin, factor Xa, or factor XII, or to other mast cell proteases,
such as chymase or mastin. Irreversibly abolishing tryptase's
catalytic activity did not alter its effects on increases in DNA
synthesis. We conclude that
-tryptase is a potent mitogenic serine
protease in cultured human airway smooth muscle cells. However, its
growth stimulatory effects in these cells occur predominantly via
nonproteolytic actions.
mast cell proteases; serine proteases; airway smooth muscle hyperplasia; noncatalytic effects of proteases
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
AIRWAY SMOOTH MUSCLE HYPERPLASIA (30) is one of several relatively irreversible structural changes that occur in the airways of asthmatic patients. Collectively, these structural changes often are referred to as airway remodeling (24). Thickening of the airway wall, resulting in part from hyperplasia of airway smooth muscle cells, has potential pathophysiological importance for several reasons. It may give rise to exaggerated decreases in airway caliber when the smooth muscle shortens by a given amount (31). Also, it may contribute to the severe, irreversible airflow obstruction that sometimes occurs in patients with refractory asthma (55). Tryptases are trypsin-like neutral serine-class proteases that are selectively expressed in mast cells and basophils (14). Tryptase is released in airways during allergen challenge in atopic subjects (56) and is present in increased concentrations in induced sputum samples obtained from asthmatic patients (25). We previously demonstrated that tryptase is an extremely potent growth factor for cultured dog airway smooth muscle cells (10). The mitogenic potential of tryptase in human cells has been established, including in human lung and dermal fibroblasts (1, 28), dermal microvascular endothelial cells (7), and H292 lung mucoepidermoid cells (12). However, it is not known whether tryptase stimulates growth in human airway smooth muscle cells. If it does, repeated episodes of mast cell degranulation, release of tryptase extracellularly, and activation of smooth muscle growth could be important events leading to thickening of the smooth muscle layer as part of airway remodeling.
In addition to tryptase, a number of other serine proteases have the capacity to stimulate cellular growth. Trypsin has mitogenic actions in some preparations of cultured vascular smooth muscle cells (9). Chymase, like tryptase, a mast cell-associated serine protease, induces potent proliferative effects in cultured myocardial cells (27) and in dermal fibroblasts (3). A number of serine proteases in the coagulation cascade are potent growth factors in the vasculature. These include thrombin (37), factor Xa (32, 39), and factor XII (26). Thrombin also stimulates mitogenesis in human airway smooth muscle cells (41), a finding of potential importance because of likely increases in airway vascular permeability that occur in asthma (48). Indeed, the fact that growth stimulation in a given cell type may occur in response to many different serine proteases raises the possibility that these growth regulatory effects of serine proteases occur via a common, relatively nonspecific effect. Thus an important issue is to determine whether mitogenic effects of tryptase in airway smooth muscle cells occur via a mechanism that is specific to tryptase vs. via mechanisms that are shared with many other mitogenic serine proteases. A related need is to compare the magnitude of tryptase's growth stimulatory capacity in airway smooth muscle cells with those of other mitogenic serine proteases. To the extent that several different serine proteases induce growth responses in airway smooth muscle cells of approximately the same magnitude, the findings would support the likelihood of nonspecific, shared mitogenic mechanisms. By contrast, if growth stimulatory effects of tryptase far exceeded those of other mitogenic serine proteases in airway smooth muscle cells, the findings would suggest that tryptase may activate the cells to grow via a relatively unique mechanism.
Regarding specific mechanisms through which tryptase may activate cells, much recent emphasis has been placed on its capacity to activate protease-activated receptor-2, one member of the relatively new class of G protein-coupled, protease-activated receptors (PARs; see Ref. 21). As a family, PARs share a unique mechanism of activation. A specific protease cleaves the receptor's NH2-terminal extracellular domain. This cleavage unmasks a new NH2 terminus that then serves as a "tethered ligand," binding intramolecularly to the body of the receptor and effecting transmembrane signaling (21). Four different PARs now have been identified (PARs 1-4). PAR-1, -3, and -4 are receptors for thrombin (21). PAR-2 is activated by trypsin and trypsin-like proteases, including tryptase, and by tissue factor and factor Xa (13). Tryptase's ability to activate PAR-2 has been documented by demonstrating its ability to cleave peptides corresponding to the NH2-terminal portion of PAR-2 (36) and to stimulate PAR-2-associated phosphoinositol hydrolysis and increases in intracellular calcium (20, 36). Immunolocalization studies in respiratory tissues have identified PAR-2 expression in human airway smooth muscle (23), and expression of functional PAR-2 has been established to occur in cultured human airway smooth muscle cells (5, 29).
It is important to note, however, that some proteases are capable of
activating cells via nonproteolytic mechanisms. For example, thrombin
binds to glycoprotein GP Ib on the surface of platelets (2). The binding is of high affinity (2),
clearly involves a site in the thrombin molecule different from its
catalytic domain (45), and does not require a proteolytic
event (45). Binding of thrombin to GP Ib
may initiate
transmembrane signaling itself or may merely serve as a necessary
preliminary event before thrombin-induced cleavage of PARs or other
surface proteins (21). There is evidence that thrombin can
induce growth in endothelial cells via both proteolytic and
nonproteolytic events (4), findings that suggest the
possibility that thrombin's binding to GP Ib
may, in itself, be
sufficient to induce mitogenesis in these cells. For tryptase, the
relative importance of proteolytic vs. nonproteolytic mechanisms for
mediating its mitogenic effects have not been evaluated extensively. However, in some prior studies, although protease inhibitors clearly attenuated tryptase's growth stimulatory effects, there was
substantial residual mitogenic activity, even in the presence of potent
and irreversible protease inhibitors (10, 44). In one
other study, on the other hand, protease inhibitors abolished
tryptase's mitogenic effects completely in human lung fibroblast cells
(1).
Our study had the following three goals: 1) to determine whether tryptase is a mitogen for cultured human airway smooth muscle cells; 2) to compare its relative strength as a mitogen compared with other mitogenic serine proteases and with classical growth factor receptor tyrosine kinases; and 3) to determine the importance of proteolytic vs. nonproteolytic mechanisms for tryptase's growth stimulatory effects in these cells.
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials. Porcine heparin (4-6 kDa), N-p-tosyl-Gly-Pro-Lys p-nitroanilide (GPK), p-amidino phenylmethanesulfonyl fluoride (p-APMSF), trypsin, Triton X-100, diisopropylfluorophosphate (DFP), and 3,4-dichloroisocoumarin (DCI) were purchased from Sigma Chemical (St. Louis, MO). Other reagents and their sources were plasminogen-free bovine thrombin, human plasma coagulation factors Xa and XII (Calbiochem, La Jolla, CA), serum-free medium (cellgro COMPLETE; Mediatech, Herndon, VA), recombinant human platelet-derived growth factor-BB homodimer (PDGF-BB), recombinant human insulin-like growth factor I (IGF-I), recombinant human basic fibroblast growth factor (bFGF), recombinant human epidermal growth factor (EGF), Moloney murine leukemia virus reverse transcriptase (MMLV RT), and Thermus aquaticus (Taq) polymerase (Life Technologies, Gaithersburg, MD). Ultraspec II was from Biotecx (Houston, TX), and succinyl-Phe-Pro-Phe-p-nitroanilide was from Bachem (Torrance, CA). Oligonucleotide primers employed in PCR reactions were synthesized by the Biomolecular Resource Center (University of California-San Francisco).
Cell culture. Primary cultures of dog tracheal smooth muscle cells were established and maintained as previously described (52). Cells were fed on alternate days and were passaged enzymatically when they approached confluence. Human cells were isolated by culture of explants of trachealis muscle obtained from individuals without respiratory disease within 12 h of death, as described previously (6). Cells isolated from three different individuals were employed in these experiments. Human cells were maintained in Ham's F-12 medium containing 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% FCS. They were maintained by feeding on alternate days and were enzymatically passaged near confluence. A549 cells were obtained from American Type Culture Collection (Manassas, VA).
Tryptase and other mast cell proteases.
Tryptase was isolated from human lung tissue, as described previously
(28). Purity of the tryptase in these isolates has been
established using chromatographic, electrophoretic, and immunologic criteria (28). This preparation is predominantly
-tryptase (personal communication, Dr. L. B. Schwartz, Medical
College of Virginia, Richmond, VA). In a few experiments, we also
employed tryptase from other sources for purposes of comparison. These were human lung tryptase from a commercial source (Calbiochem), from
human mast cell leukemia cells (HMC-1; see Ref. 11), and from dog mastocytoma cells (18). Dog mast cell
-chymase
and a novel tryptase-like serine protease known as dog mast cell
protease-3 (dMCP-3; see Ref. 57) or mastin
(16) also were isolated as described previously
(57).
Assay of serine protease activity. Catalytic activity of tryptase was measured by assessing its ability to cleave GPK (47). Tryptase was added to 50 mM Tris buffer, pH 7.7, containing 120 mM NaCl, 20 µg/ml heparin, and 100 µM GPK (final volume: 100 µl). Rates of GPK hydrolysis were determined at room temperature for 3 min by following the change in absorbance at 405 nm using a Beckman spectrophotometer. The concentration of tryptase was calculated from the amount of cleaved substrate (molar extinction coefficient = 8,800), assuming a molecular weight of 140,000 for tetrameric tryptase (42). Catalytic activities of dMCP-3 (or mastin) and thrombin also were confirmed using this assay. Proteolytic activity of chymase was confirmed by monitoring its cleavage (at 405 nm and 37°C) of 80 µM succinyl-Phe-Pro-Phe-p-nitroanilide in 30 mM Tris buffer containing 1 M NaCl, pH 8.0 (17).
Tryptase catalytic inhibition. To assess proteolytic vs. nonproteolytic effects, we explored available techniques potentially suitable for irreversibly inhibiting tryptase's catalytic activity. We reasoned that reversible inhibitors could be inadequate for our purposes because of their possible degradation during the 48 h required to assess changes in DNA synthesis. We considered the following three different irreversible serine protease inhibitors: DFP, DCI (43), and p-APMSF (33). A disadvantage of DFP is its toxicity. DCI (100 µM) effectively inhibited catalytic activity but caused significant cytotoxicity in our cellular preparations. p-APMSF proved to be an ideal irreversible inhibitor. This compound is a specific, irreversible, noncytotoxic inhibitor of the class of serine proteases that cleaves substrates after lysine or arginine (33), and tryptase falls into this class (46). In our experiments, tryptase (10.5-27 nM) was incubated with p-APMSF (10 µM) for 100-120 min at 4°C in 10 mM BisTris buffer, pH 6.1. As a control, tryptase was incubated with p-APMSF diluent alone (1:1 acetonitrile-dimethylformamide). Incubates then were diluted 1:5 in serum-free cellgro COMPLETE media, pH 7.4, and placed on ice for 3-5 h before application to cells in 96-well plates. To test for its possible cytotoxic effects, p-APMSF that had been incubated alone was added to wells containing either serum-free media or PDGF-BB, and the effects on DNA synthesis (see below) were determined. Before application on cells, p-APMSF-treated tryptase was assayed for completeness of catalytic inhibition using the GPK assay, as described above. In some experiments, to test for irreversibility of the catalytic inhibition, we removed aliquots of media overlying cells that contained p-APMSF-treated tryptase after 24 h and confirmed that it still was unable to cleave GPK. In other experiments, trypsin (8.9-125.1 nM) was incubated with p-APMSF in an identical manner to test for mitogenic effects of p-APMSF-treated trypsin.
DNA synthesis. To quantify DNA synthesis in the cells, we measured the incorporation of bromodeoxyuridine (BrDU) into cellular DNA using an enzyme-linked immunosorbent assay (ELISA), as we described previously (10). For studies in human cells, passage 5-9 cells were seeded at a density of 10,000 cells/well in 96-well format. After 24 h in F-12 media containing 10% FCS, the cells in each well were washed one time with PBS and then starved for 24 h in 100 µl of serum-free F-12 media before the addition of mitogens. BrDU was introduced 24-48 h after the addition of mitogens. For dog cells, passages 1-5 were used for quantifying DNA synthesis and were starved in cellgro COMPLETE serum-free media. Mitogens were introduced in the cultures, and the BrDU (10 µM) was added 24-48 h later.
Cell counts. Human airway smooth muscle cells were seeded at a density of 10,000 cells/well in 96-well format. After 24 h starvation in serum-free F-12 media, mitogens or media alone were added to cells at day 0. Counts were performed 48 and 96 h later ("days 2 and 4") from triplicate wells using a hemocytometer after enzymatic detachment of cells.
PAR-2 expression in human airway smooth muscle cells. Previous investigators have demonstrated that PAR-2 is expressed in cultured human airway smooth muscle cells (29). To confirm that the cells employed in our study also express this receptor, we used PCR. RNA was isolated from five different preparations of human airway smooth cells, at a confluent or near-confluent stage, using Ultraspec II. As positive and negative controls, we also isolated RNA from A549 cells and human platelets, which express PAR-2 in abundance and not at all, respectively (8). Single-stranded cDNA was synthesized from the RNA using MMLV RT. Each reaction was carried out in 20 µl containing 2 µg RNA as template, 0.6 mM concentrations of each dNTP, random hexamers (50 ng/reaction), RNasin (20 U/reaction), 50 nM Tris (pH 8.3), 3 mM MgCl2, 75 mM KCl, and 10 mM dithiothreitol. Reverse transcription was carried out using 200 units of MMLV RT per reaction at room temperature for 10 min followed by 42°C for 45 min and then heat inactivation for 5 min at 95°C.
For PCR, oligonucleotide primers used for amplification of PAR-2 gene fragments were as follows: forward primer (complementary to nucleotides 159-179 in exon 1), 5'-CAGCGCGGCGTGGCTGCTGGG; reverse primer (complementary to nucleotides 446-466 in exon 2), 5'-AAGACCCACAGGGCCATGCCG (8). The expected size of the amplified product was 287 bp (8). To test for RNA integrity and efficiency of the RT reactions in each sample, PCR also was carried out with primers for identification of ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Tryptase is a mitogen for human airway smooth muscle cells.
Human lung tryptase in nanomolar concentrations effectively stimulated
BrDU incorporation into newly synthesized DNA (Fig. 1). The mitogenic effects of tryptase
were concentration dependent, and maximum stimulation occurred at
concentrations of 20-30 nM. Concentrations of tryptase >20 nM
elicited 33-46% of the BrDU uptake occurring in the presence of
10% FCS (data not shown). Exposure to tryptase for 4 days produced
significant increases in smooth muscle cell numbers compared with
numbers when cells were maintained for the same time period under
basal, serum-free conditions (Fig. 2).
Tryptase purified from HMC-1 mastocytoma cells (11) and
from dog mastocytoma cells (18) also promoted BrDU
incorporation in human cells (data not shown).
|
|
Tryptase is an extremely strong mitogen for human airway smooth
muscle cells when its maximum effects on increased DNA synthesis are
compared with those of peptide growth factors and other mitogenic
serine proteases.
In cultured human airway smooth muscle, maximum increases in BrDU
incorporation induced by large concentrations of tryptase were
comparable to those induced by large concentrations of PDGF-BB and
bFGF, and the responses to tryptase were substantially greater than
those induced by large concentrations of EGF (Fig.
3A). IGF-I did not induce
detectable increases in BrDU incorporation at any concentration in the
human cells (Fig. 3A). Compared with the maximum effects of
tryptase, increases in BrDU incorporation in response to the other
mitogenic serine proteases tested (thrombin, factor Xa, and factor XII)
were relatively small.
|
|
Tryptase's mitogenic effects in human airway smooth muscle cells
are largely nonproteolytic.
Treatment of tryptase with p-APMSF invariably inhibited its
proteolytic activity by 99% or more. In human airway smooth muscle cells, growth stimulatory effects of tryptase were not altered by prior
treatment by p-APMSF (Fig.
5B). Results shown are from 10 different experiments, each performed in triplicate, and in none of
these experiments was there an apparent difference between p-APMSF-treated and -untreated tryptase. By contrast, in dog
cells, the tryptase response clearly was attenuated by
p-APMSF (Fig. 5A). The total and irreversible
inhibition of tryptase's proteolytic activity after treatment with
p-APMSF was confirmed upon the addition of
p-APMSF-treated tryptase to cells and after a period of
24 h under conditions identical to those employed in the BrDU
assay. In the same experiments, we tested the effects of
p-APMSF treatment on responses to PDGF in both human and dog
cells. Concentrations of PDGF employed in these experiments were
adjusted such that PDGF-induced mitogenic responses approximated those
achieved in response to tryptase. Treatment of PDGF with
p-APMSF had no significant attenuatory effects on responses
to PDGF in either human or dog cells (Fig. 5). In the human cells,
human lung tryptase from a commercial source (Calbiochem) also was a
potent mitogen, and p-APMSF treatment had no significant
attenuating effects on its mitogenic activity (data not shown).
|
Human airway smooth muscle cells employed in these experiments
express PAR-2.
PCR yielded DNA bands of the expected size from each of the five
different preparations of human airway smooth muscle cells, although
there was variability in band intensity compared with that of -actin
(Fig. 6). Using the PAR-2 primers, we
also identified intense bands of the appropriate size using RNA
preparations from A549 cells, but no bands were seen using RNA from
human platelets (data not shown). We also identified an intense band of
the appropriate size when a Hind III-linearized human PAR-2
cDNA was used as template with the PAR-2 primers (data not shown). The
findings indicate that the preparations of human cells employed in our
experiments express PAR-2, as reported previously in other preparations
of cultured human airway smooth muscle cells by other investigators (5, 29).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In this study, we found that mast cell tryptase produced concentration-dependent increases in DNA synthesis in cultured human airway smooth muscle cells (Fig. 1), as in cultured dog tracheal smooth muscle cells reported previously (10). Tryptase-induced increases in DNA synthesis resulted in demonstrable and significant increases in cell numbers in the human cells (Fig. 2). The increases in DNA synthesis occurred over the 1-30 nM range of tryptase concentrations, a concentration range with potential relevance in vivo based on previous estimates of mast cell densities in the smooth muscle layer of human bronchi (35) and of tryptase concentrations per human lung mast cell (22). In our experiments, the maximum increases in DNA synthesis induced by tryptase were comparable to those in response to several classical peptide growth factors and substantially greater than to other mitogenic serine proteases (Fig. 3). Bolstering the strength of these findings is our prior extensive validation of the BrDU ELISA as an accurate means of quantifying DNA synthesis in cultured airway smooth muscle cells (10). As reported by prior investigators in other preparations of human airway smooth muscle cells (29), the human cells employed in our experiments appeared to express PAR-2 (Fig. 6). However, a major and somewhat surprising finding of our experiments was that tryptase-induced mitogenic responses in the human cells were largely via nonproteolytic mechanisms (Fig. 5B); therefore, PAR-2 activation likely was not involved in mediating tryptase's growth stimulatory effects in these cells.
In a previous study, we showed that tryptase-induced mitogenesis in
cultured dog airway smooth muscle cells was attenuated by a protease
inhibitor (10), and we confirmed this finding in the
present study (Fig. 5A). For that reason, at the outset of
the current study, we were curious to compare the magnitude of
mitogenic responses to tryptase with those of other mitogenic serine
proteases to determine whether or not tryptase's effects reflected a
general, nonspecific growth stimulatory response to serine proteases.
We tested several other serine proteases. Chymase, a mast cell protease
with chymotrypsin-like activity, has mitogenic effects on
intramyocardial cells (27) and 3T3 fibroblasts
(3). The cellular mechanism is not known but may relate to
chymase's potent angiotensin-converting enzyme activity
(50). Human coagulation factor Xa is a potent growth
factor for vascular smooth muscle and endothelial cells, perhaps
mediated via activation of effector cell protease receptor-1 (EPR-1;
see Ref. 39). Current evidence suggests that factor Xa
binds with high affinity to EPR-1 and then may initiate growth via a
secondary event that requires its (factor Xa's) catalytic site
(39). Factor XII stimulates growth of hepatocytes and
aortic smooth muscle, endothelial, and alveolar type 2 cells
(28). Intriguingly, the factor XII molecule contains EGF-homologous domains, although recent evidence argues against EGF
receptor activation as the mechanism for factor XII's growth stimulatory activity (28). Potent mitogenic effects of
thrombin in the vasculature may occur via proteolytic activation of
PARs (21) and possibly via nonproteolytic binding and
activation of GP Ib (2). In our experiments, thrombin
clearly was a mitogen in both human and dog airway smooth muscle cells
(Fig. 3, A and B), as described previously in
human cells by other investigators (41). However, tryptase
stimulated maximal increases in DNA synthesis to a much greater extent
than any of these other serine proteases. The findings suggest that
tryptase's growth stimulatory effects in cultured airway smooth muscle
cells do not reflect a nonspecific effect of many different serine
proteases. Instead, a mechanism relatively unique to tryptase likely is
involved. Specificity of the mechanisms through which different
proteases induce growth stimulatory effects also is suggested by the
prior observation that tryptase was not a mitogen for cultured vascular smooth muscle cells (28), where the coagulation proteases
would be expected to have relatively potent growth stimulatory effects.
Trypsin is a mitogen in some cells (9); therefore, during
the course of our experiments, we were interested in determining its
potential growth stimulatory effects in airway smooth muscle cells. Not
surprisingly, we were unable to test the full range of trypsin
concentrations in our BrDU ELISAs because trypsin concentrations >10
nM detached the smooth muscle cells from their substrate. These
observations, coupled with the fact that tryptase never caused such
detachment, are consistent with a general lack of specificity at the
substrate P3 locus for trypsin's proteolytic actions vs. the
relatively narrow range of extended peptide substrates cleaved by
tryptase (51). Trypsin may induce growth
stimulatory effects via its insulinomimetic effects (49).
Thus tryptic cleavage of the -subunit of the insulin receptor
resulted in autophosphorylation of the
-subunit and initiation of
transmembrane signaling (49). Cleavage of the
-subunit
may have relieved its tonic inhibition of
-subunit phosphorylation
and thus allowed signaling and growth induction to proceed just as if
the receptor were occupied by insulin (49). In our
experiments, we considered the possibility that the IGF-I receptor
might be a site of action for tryptase effects because of this known
insulinomimetic activity of trypsin, the structural similarities of
insulin and IGF-I receptors (53), and the potent
growth-promoting effects of IGF-I in cultured dog airway smooth muscle
cells (Fig. 3B). We defined concentrations of trypsin that
produced a small mitogenic response without detaching cells from the
substratum. Concentrations of tryptase were chosen to match these small
mitogenic responses. We then sought to determine the effects of
threshold concentrations of each protease on responses to IGF-I.
Interestingly, trypsin and IGF-I induced increases in DNA synthesis
that were additive (Fig. 4B). The finding is consistent with
activation by trypsin and IGF-I of the same cell surface receptor,
possibly the IGF-I receptor, although more information would be needed
to establish this mechanism. In contrast, responses to tryptase and
IGF-I were synergistic (Fig. 4A), and the findings suggested
that these two agents employed separate modes of activation and
possibly separate, rather than a shared, receptor(s) (28).
In our experiments, we used p-APMSF to inhibit tryptase's proteolytic actions irreversibly (10, 33). Other more commonly used inhibitors of tryptase's proteolytic activity include leupeptin, antipain, and benzamidine (15). All have the potential problems of reversibility and low potency (15). Compounds such as bis(5-amidino-2-benzimidazolyl)methane (15) and APC366 (19) have improved potency but still are reversible. p-APMSF (33) is well suited for use in relatively lengthy proliferation assays in vitro because it effectively and irreversibly blocks virtually all catalytic activity of tryptase at low concentrations without inducing cytotoxic effects (33). In our experiments, we established that p-APMSF inhibited tryptase's catalytic activity by 99% or more in every experiment, and the inhibition persisted throughout the time course of the mitogenic assays. Our principal finding was that treatment of tryptase with p-APMSF significantly attenuated, but failed to abolish, increases in DNA synthesis in cultured dog airway smooth muscle cells (Fig. 5B) on the one hand but did not significantly alter tryptase-induced responses in human cells on the other hand (Fig. 5A). In the human cells, it seems unlikely that a very small amount of residual catalytic activity in p-AMSF-treated-tryptase could account for its persistently potent mitogenic activity, particularly when the relationships between tryptase concentration and mitogenic response are taken into consideration (Fig. 1). The findings raise the possibility that tryptase has the capacity to induce its mitogenic effects in airway smooth muscle cells via both proteolytic and nonproteolytic mechanisms, with each mechanism being of different degrees of importance depending on the specific cell type and experimental conditions.
Although tryptase-induced activation of PAR-2 clearly is one potential
proteolytic mechanism for tryptase's effects (1, 20, 36),
we can only speculate about possible nonproteolytic mechanisms. In
bovine airway smooth muscle cells, potent proliferative responses to
-hexosaminidase and other mannosyl-rich glycoproteins are mediated
by specific mannose receptors (34). The purified tryptase
from human lung used in our studies most likely is composed of a
combination of
1- and
2-isoforms that
have two and one NH2-linked glycosylation site(s) per
monomer, respectively (54). The crystal structure of
tetrameric human
-tryptase has several glycosylated residues on the
outer surface of the molecule in a location where such residues likely
would be accessible for binding to cell surface mannose receptors
(42). Such a mechanism would account for nonproteolytic
activation of cellular growth by tryptase in airway smooth muscle cells.
In summary, tryptase is an extremely potent mitogen in cultured human airway smooth muscle cells. Therefore, its repeated release in the airways after mast cell degranulation (56) could contribute importantly to the smooth muscle hyperplasia and remodeling that occur in the airways of asthmatic patients (30). Many have assumed that all biological effects of extracellular tryptase are mediated via its catalytic site, but the tryptase tetramer has a complicated structure with the potential to exert both nonproteolytic and proteolytic actions (42). To our knowledge, all current efforts to develop tryptase inhibitors focus on attenuating its catalytic effects exclusively (15, 19). In this regard, our finding that tryptase's growth stimulatory effects in human airway smooth muscle cells occur largely via nonproteolytic mechanisms is important. The finding suggests that more complete information about the specific cellular mechanisms for tryptase's growth stimulatory effects may be needed before compounds can be developed that would be predicted to inhibit tryptase-induced mitogenesis in vivo with a full degree of effectiveness.
![]() |
ACKNOWLEDGEMENTS |
---|
This work was supported by the Research Service of the Department of Veterans Affairs, National Heart, Lung, and Blood Institute Program Project Grant HL-24136, and the National Asthma Campaign (United Kingdom).
![]() |
FOOTNOTES |
---|
Address for reprint requests and other correspondence: J. K. Brown, Pulmonary and Critical Care Medicine Section (111-D), Dept. of Veterans Affairs Medical Center, 4150 Clement St., San Francisco, CA 94121 (E-mail: jkbrown{at}itsa.ucsf.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 27 February 2001; accepted in final form 25 September 2001.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Akers, IA,
Parsons M,
Hill MR,
Hollenberg MD,
Sanjar S,
Laurent GJ,
and
McAnulty RJ.
Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2.
Am J Physiol Lung Cell Mol Physiol
278:
L193-L201,
2000
2.
Akiba, S,
Kawauchi T,
and
Sato T.
Acceleration of Ca2+ ionophore-induced arachidonic acid liberation by thrombin without the proteolytic action toward the receptor in human platelets.
Eur J Biochem
259:
643-650,
1999
3.
Algermissen, B,
Hermes B,
Feldman-Boeddeker I,
Bauer F,
and
Henz BM.
Mast cell chymase and tryptase during tissue turnover: analysis on in vitro mitogenesis of fibroblasts and keratinocytes and alterations in cutaneous scars.
Exp Dermatol
8:
193-198,
1999[ISI][Medline].
4.
Bar-Shavit, R,
Benezra M,
Eldor A,
Hy-Am E,
Fenton JW,
Wilner DG,
and
Vlodavsky I.
Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: nonenzymatic mode of action.
Cell Regul
1:
453-463,
1990[ISI][Medline].
5.
Berger, P,
Tunon-De-Lara M,
Savineau J,
and
Marthan R.
Signal transduction in smooth muscle. Selected Contribution: tryptase-induced PAR-2-mediated Ca2+ signaling in human airway smooth muscle cells.
J Appl Physiol
91:
995-1003,
2001
6.
Billington, CK,
Joseph SK,
Swan C,
Scott MG,
Jobson TM,
and
Hall IP.
Modulation of human airway smooth muscle proliferation by type 3 phosphodiesterase inhibition.
Am J Physiol Lung Cell Mol Physiol
276:
L412-L419,
1999
7.
Blair, RJ,
Meng H,
Marchese MJ,
Ren S,
Schwartz LB,
Tonnesen MG,
and
Gruber BL.
Human mast cells stimulate vascular tube formation.
J Clin Invest
99:
2691-2700,
1997
8.
Bohm, SK,
Kong W,
Bromme D,
Smeekens SP,
Anderson DC,
Connolly A,
Kahn M,
Nelken NA,
Coughlin SR,
Payan DG,
and
Bunnett NW.
Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2.
Biochem J
314:
1009-1016,
1996[ISI][Medline].
9.
Bono, F,
Lamarche I,
and
Herbert JM.
Induction of vascular smooth muscle cell growth by selective activation of the proteinase activated receptor-2 (PAR-2).
Biochem Biophys Res Commun
241:
762-764,
1997[ISI][Medline].
10.
Brown, JK,
Tyler CL,
Jones CA,
Ruoss SJ,
Hartmann T,
and
Caughey GH.
Tryptase, the dominant secretory granular protein in human mast cells, is a potent mitogen for cultured dog tracheal smooth muscle cells.
Am J Respir Cell Mol Biol
13:
227-236,
1995[Abstract].
11.
Butterfield, JH,
Weiler DA,
Hunt LW,
Wynn SR,
and
Roche PE.
Purification of tryptase from a human mast cell line.
J Leukoc Biol
47:
409-419,
1990[Abstract].
12.
Cairns, JA,
and
Walls AF.
Mast cell tryptase is a mitogen for epithelial cells. Stimulation of IL-8 production and intracellular adhesion molecule-1 expression.
J Immunol
156:
275-283,
1995[Abstract].
13.
Camerer, E,
Huang W,
and
Coughlin SR.
Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa.
Proc Natl Acad Sci USA
97:
5255-5260,
2000
14.
Caughey, GH.
Of mites and men: trypsin-like proteases in the lungs.
Am J Respir Cell Mol Biol
16:
621-628,
1997[Abstract].
15.
Caughey, GH,
Raymond WW,
Bacci E,
Lombardy RJ,
and
Tidwell RR.
Bis(5-amidino-2-benzimidazolyl)methane and related amidines are potent, reversible inhibitors of mast cell tryptases.
J Pharmacol Exp Ther
264:
676-682,
1993[Abstract].
16.
Caughey, GH,
Raymond WW,
Blount JL,
Hau LW,
Pallaoro M,
Wolters PJ,
and
Verghese GM.
Characterization of human gamma-tryptases, novel members of the chromosome 16p mast cell tryptase and prostasin gene families.
J Immunol
164:
6566-6575,
2000
17.
Caughey, GH,
Viro NF,
Lazarus SC,
and
Nadel JA.
Purification and characterization of dog mastocytoma chymase: identification of an octapeptide conserved in chymotryptic leukocyte proteinases.
Biochim Biophys Acta
952:
142-149,
1988[ISI][Medline] (published erratum appears in Biochim Biophys Acta 996: 263, 1989).
18.
Caughey, GH,
Viro NF,
Ramachandran J,
Lazarus SC,
Borson DB,
and
Nadel JA.
Dog mastocytoma tryptase: affinity purification, characterization and amino-terminal sequence.
Arch Biochem Biophys
258:
555-563,
1987[ISI][Medline].
19.
Clark, JM,
Abraham WM,
Fishman CE,
Forteza R,
Ahmed A,
Cortes A,
Warne RL,
Moore WR,
and
Tanaka RD.
Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep.
Am J Respir Crit Care Med
152:
2076-2083,
1995[Abstract].
20.
Corvera, CU,
Déry O,
McConalogue K,
Bohm S,
Khitin L,
Caughey GH,
Payan DG,
and
Bunnett NW.
Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2.
J Clin Invest
100:
1383-1393,
1997
21.
Coughlin, SR.
Thrombin signaling and protease-activated receptors.
Nature
407:
258-264,
2000[ISI][Medline].
22.
Craig, SS,
and
Schwartz LB.
Tryptase and chymase, markers of distinct types of human mast cells.
Immunol Res
8:
130-148,
1989[ISI][Medline].
23.
D'Andrea, MR,
Derian CK,
Leturcq D,
Baker SM,
Brunmark A,
Ling P,
Darrow AL,
Santulli R,
Brass LF,
and
Andrade-Gordon P.
Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues.
J Histochem Cytochem
46:
157-164,
1998
24.
Elias, JA.
Airway remodeling in asthma. Unanswered questions.
Am J Respir Crit Care Med
161:
S168-S171,
2000
25.
Fahy, JV,
Liu J,
Wong H,
and
Boushey HA.
Cellular and biochemical analysis of induced sputum from asthmatic and healthy subjects.
Am Rev Respir Dis
147:
1126-1131,
1993[ISI][Medline].
26.
Gordon, EM,
Venkatesan N,
Salazar R,
Tang H,
Schmeidler-Sapiro K,
Buckley S,
Warburton D,
and
Hall FL.
Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase.
Proc Natl Acad Sci USA
93:
2174-2179,
1996
27.
Hara, M,
Matsumori A,
Ono K,
Kido H,
Hwang M,
Miyamoto T,
Iwasaki A,
Okada M,
Nakatani K,
and
Sasayama S.
Mast cells cause apoptosis of cardiomyocytes and proliferation of other intramyocardial cells in vitro.
Circulation
100:
1443-1449,
1999
28.
Hartmann, T,
Ruoss SJ,
Raymond WW,
Seuwen K,
and
Caughey GH.
Human tryptase as a potent, cell specific mitogen: role of signaling pathways in synergistic responses.
Am J Physiol Lung Cell Mol Physiol
262:
L528-L534,
1992
29.
Hauck, RW,
Schulz C,
Schömig A,
Hoffman RK,
and
Panettieri RA, Jr.
-Thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors.
Am J Physiol Lung Cell Mol Physiol
277:
L22-L29,
1999
30.
Hossain, S.
Quantitative measurement of bronchial muscle in men with asthma.
Am Rev Respir Dis
107:
99-109,
1973[ISI][Medline].
31.
James, AL,
Pare PD,
and
Hogg JC.
The mechanics of airway narrowing in asthma.
Am Rev Respir Dis
139:
242-246,
1989[ISI][Medline].
32.
Ko, FN,
Yang YC,
Huang SC,
and
Ou JT.
Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cell of rat.
J Clin Invest
96:
1493-1501,
1996.
33.
Laura, R,
Robison DJ,
and
Bing DH.
(p-Amidinophenyl)methanesulfonyl fluoride, an irreversible inhibitor of serine proteases.
Biochemistry
19:
4859-4864,
1980[ISI][Medline].
34.
Lew, DB,
Songu-Mize E,
Pontow SE,
Stahl PD,
and
Rattazzi MC.
A mannose receptor mediates mannosyl-rich glycoprotein-induced mitogenesis in bovine airway smooth muscle cells.
J Clin Invest
94:
1855-1863,
1994[ISI][Medline].
35.
Matin, R,
Tam EK,
Nadel JA,
and
Caughey GH.
Distribution of chymase-containing mast cells in human bronchi.
J Histochem Cytochem
40:
781-786,
1992
36.
Molino, M,
Barnathan ES,
Numerof R,
Clark J,
Dreyer M,
Cumashi A,
Hoxie JA,
Schechter N,
Woolkalis M,
and
Brass LF.
Interactions of mast cell tryptase with thrombin receptors and PAR-2.
J Biol Chem
272:
4043-4049,
1997
37.
Molloy, CJ,
Pawlowski JE,
Taylor DS,
Turner CE,
Weber H,
Peluso M,
and
Seiler SM.
Thrombin receptor activation elicits rapid protein tyrosine phosphorylation and stimulation of the Raf-1/MAP Kinase pathway preceding delayed mitogenesis in cultured rat aortic smooth muscle cells.
J Clin Invest
97:
1173-1183,
1996
38.
Mullhaupt, B,
Feren A,
Fodor E,
and
Jones A.
Liver expression of epidermal growth factor RNA.
J Biol Chem
269:
19667-19670,
1994
39.
Nicholson, AC,
Nachman Rl,
Altieri DC,
Summers BD,
Ruf W,
Edgington TS,
and
Hajjar DP.
Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa.
J Biol Chem
271:
28407-28413,
1996
40.
Nudel, U,
Zakut R,
Shani M,
Neuman S,
Levy Z,
and
Yaffe D.
The nucleotide sequence of the rat cytoplasmic beta-actin gene.
Nucleic Acids Res
11:
1759-1771,
1983[Abstract].
41.
Panettieri, RA, Jr,
Hall IP,
Maki CS,
and
Murray RK.
Alpha-thrombin increases cytosolic calcium and induces human airway smooth muscle cell proliferation.
Am J Respir Cell Mol Biol
13:
205-216,
1995[Abstract].
42.
Pereira, PJ,
Bergner A,
Macedo-Ribero S,
Huber R,
Matschiner G,
Fritz H, CPS,
and
Bode W.
Human -tryptase is a ring-like tetramer with active sites facing a central pore.
Nature
392:
306-311,
1998[ISI][Medline].
43.
Powers, JC,
and
Kam CM.
Isocoumarin inhibitors of serine peptidases.
Methods Enzymol
244:
442-457,
1994[ISI][Medline].
44.
Ruoss, SJ,
Hartmann T,
and
Caughey GH.
Mast cell tryptase is a mitogen for cultured fibroblasts.
J Clin Invest
88:
493-499,
1991[ISI][Medline].
45.
Schaeffer, P,
Riera E,
Dupuy E,
and
Herbert J.
Nonproteolytic activation of the thrombin receptor promotes human umbilical vein endothelial cell growth but not intracellular Ca2+, prostacyclin, or permeability.
Biochem Pharmacol
53:
487-491,
1997[ISI][Medline].
46.
Schwartz, LB.
Tryptase: a mast cell serine protease.
Methods Enzymol
244:
88-100,
1994[ISI][Medline].
47.
Schwartz, LB,
and
Bradford TR.
Regulation of tryptase from human lung mast cells by heparin. Stabilization of the active tetramer.
J Biol Chem
261:
7372-7379,
1986
48.
Shiels, IA,
Bowler SD,
and
Taylor SM.
Airway smooth muscle proliferation in asthma: the potential of vascular leakage to contribute to pathogenesis.
Med Hypotheses
45:
37-40,
1995[ISI][Medline].
49.
Shoelson, SE,
White MF,
and
Kahn CR.
Tryptic activation of the insulin receptor. Proteolytic truncation of the alpha-subunit releases the beta-subunit from inhibitory control.
J Biol Chem
263:
4852-4860,
1988
50.
Takai, S,
Jin D,
Sakaguchi M,
and
Miyazaki M.
Chymase-dependent angiotensin II formation in human vascular tissue.
Circulation
100:
654-658,
1999
51.
Tanaka, T,
McRae BJ,
Cho K,
Cook R,
Fraki JE,
Johnson DA,
and
Powers JC.
Mammalian tissue trypsin-like enzymes.
J Biol Chem
258:
13552-13557,
1983
52.
Tom-Moy, M,
Madison JM,
Jones CA,
de Lanerolle P,
and
Brown JK.
Morphologic characterization of cultured smooth muscle cells isolated from the tracheas of adult dogs.
Anat Rec
218:
313-328,
1987[ISI][Medline].
53.
Ullrich, A,
Bell JR,
Chen EY,
Herrera R,
Petruzzelli LM,
Dull TJ,
Gray A,
Coussens L,
Liao YC,
Tsubokawa M,
Mason A,
Seeburg PH,
Grunfeld C,
Rosen OM,
and
Ramachandran J.
Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes.
Nature
313:
756-761,
1985[ISI][Medline].
54.
Vanderslice, P,
Ballinger SM,
Tam EK,
Goldstein SM,
Craik CS,
and
Caughey GH.
Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family.
Proc Natl Acad Sci USA
87:
3811-3815,
1990[Abstract].
55.
Wenzel, SE.
Proceedings of the ATS workshop on refractory asthma. Current understandings, recommendations, and unanswered questions.
Am J Respir Crit Care Med
162:
2341-2351,
2000
56.
Wenzel, SE,
Fowler A,
and
Schwartz LB.
Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma.
Am Rev Respir Dis
137:
1002-1008,
1988[ISI][Medline].
57.
Yezzi, MJ,
Hsieh IE,
and
Caughey GH.
Mast cell and neutrophil expression of dog mast cell protease-3. A novel tryptase-related serine protease.
J Immunol
152:
3064-3072,
1994